Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Protalix BioTherapeutics, Inc. | tv486893_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Protalix BioTherapeutics, Inc. | tv486893_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Protalix BioTherapeutics, Inc. | tv486893_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Protalix BioTherapeutics, Inc. | tv486893_ex31-1.htm |
| EX-10.16 - EXHIBIT 10.16 - Protalix BioTherapeutics, Inc. | tv486893_ex10-16.htm |
| 10-K - FORM 10-K - Protalix BioTherapeutics, Inc. | tv486893_10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-208004) and on Form S-8 (No. 333-148983, No. 333-182677 and No. 333-203960) of Protalix BioTherapeutics, Inc. of our report dated March 6, 2018, relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
| /s/ Kesselman & Kesselman | |
| Kesselman & Kesselman | |
| Certified Public Accountants (lsr.) | |
| A member firm of PricewaterhouseCoopers International Limited | |
| Tel-Aviv, Israel | |
| March 6, 2018 | |